Search for: [Abstract = "The oncological diseases are still a challenge to clinicians and inspire the search for new diagnostic and therapeutic procedures. Lately radioisotope therapy with 90Y\-labelled compounds has been introduced in the treatment of neuroendocrine tumours and non\-Hodgkin’s lymphomas. 90Y is the emitter of beta radiation of the energy high enough to directly influence the tumour biology. Its properties enable the treatment without necessity of the patient’s hospitalisation. For the successful therapy an appropriate ligand should be chosen to carry the isotope to the place of its action. Ligands influence both the course and the side effects of the treatment. Yttrium connected by chelating agent Tiuxetan to the monoclonal antibody against antigen CD20\+ expressed on the surface of type B lymphocytes is used in the non\-Hodgkin lymphomas therapy. It enables the direct action of the radiation not only on the tumour, but on the adjacent neoplasmatic cells not expressing the antigens on their surface as well \(so called cross\-fire effect\). In the treatment of neuroendocrine tumours the somatostatin analogue labelled with radioactive isotope is utilised. Ligand \- chelator \- \[DOTA, Tyr3\] complex is characterised by the greatest affinity to somatostatin receptor type 2, which is expressed in most of the NETs. The radioisotope therapy of NETs is used in the patients with disseminated disease or"]

Number of results: 1